Keywords..

Pert treatment goals

Follow the Link  Refresh your knowledge

Effective Creon® Dosing

Follow the Link  Get up to date

Resources for practice & patient

Follow the Link  Find support

References

  1. Singh VK, Haupt ME, Geller DE, Hall JA, Quintana Diez PM. Less common etiologies if exocrine pancreatic insufficency. World J Gastroenterol 2017; 23(39):7059-7076

You will now leave the Creon patient website and go to the Creon Track site where you can join the Creon Track patient support programme

Would you like to proceed to the Creon Track registration website?

OK
NO

© 2019 Mylan. All rights reserved.

Adverse events should be reported. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard . By reporting side effects you can help provide more information on the safety of this medicine. You should also inform the company who markets Creon in the UK directly via ukpharmacovigilance@mylan.com or +44 (0)800 121 8267.

This content is intended for UK healthcare professionals.

Registered Number: 09429449 England, Registered Office: Trident Place, Building 4, Mosquito Way, Hatfield, Hertfordshire, England, AL10 9UL. CRE-2019-0427 DOP: August 2019.

For more information visit Mylan.co.uk
©2019 Mylan N.V. All Rights Reserved.